Skip to content
Screener

BioMarin Pharmaceuticals BMRN Pre-Tax Income

Pre-Tax Income at other companies

Sarepta Therapeutics, Inc. logo
Sarepta Therapeutics, Inc.SRPT
-$1.75M-101%
PTC Therapeutics logo
PTC TherapeuticsPTCT
-$2.46M-100%
Zevra Therapeutics, Inc. logo
Zevra Therapeutics, Inc.ZVRA
$12.79M-83.4%
Opko Health logo
Opko HealthOPK
-$13.4M+91.8%
Krystal Biotech, Inc. logo
Krystal Biotech, Inc.KRYS
$61.44M+40.9%

Other financials

Income statement

See full
Revenue$989.7M+19.9%
Gross profit$786.9M+16.5%
Operating income$110.9M-59.9%
Net income$44.8M-81.4%
EPS (diluted)$0.23-81.3%

Balance sheet

See full
Cash & equivalents$874.0M-28.0%
Total debt$4.2B+598%
Total equity$6.3B+4.9%
Total assets$11.7B+57.2%

Cash flow

See full
Operating cash flow$168.1M-9.3%
CapEx$28.8M+68.5%
Free cash flow$139.3M-17.2%

Valuation

See full
Market cap$11.58B-0.6%
Enterprise value$14.89B+34.9%
P/E32.2×-34.7×
P/S3.4×-0.4×

Profitability

See full
Gross margin76.1%-3.4pp
Operating margin19.9%+7.2pp
Net margin16.8%+5.1pp
FCF margin21.7%-1.0pp

Returns & leverage

See full
Return on equity9.1%+2.8pp
Debt / equity0.7×+0.6×
Current ratio2.4×-3.2×

Where this comes from

Reported directly by BioMarin Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest.

The source filing: BioMarin Pharmaceuticals’s 10-Q, filed August 6, 2026.

Filed
Aug 6, 2026, 4:14 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001048477-26-000016
Line itemThree Months Ended June 30, 2026Three Months Ended June 30, 2025Six Months Ended June 30, 2026Six Months Ended June 30, 2025
Interest income10,48018,82733,04037,840
Interest expense(63,295)(2,679)(78,253)(5,542)
Other income, net3,2794,8337,2402,879
INCOME BEFORE INCOME TAXES61,384297,868202,587535,957
Provision for income taxes16,62257,33652,298109,739
NET INCOME$44,762$240,532$150,289$426,218
EARNINGS PER SHARE, BASIC$0.23$1.25$0.78$2.23
EARNINGS PER SHARE, DILUTED$0.23$1.23$0.77$2.19

Item 1. Financial Statements

FAQ

What is BioMarin Pharmaceuticals's pre-tax income?
BioMarin Pharmaceuticals (BMRN) reported pre-tax income of $61.38M in Q2 2026.
How has BioMarin Pharmaceuticals's pre-tax income changed year-over-year?
BioMarin Pharmaceuticals's pre-tax income decreased by 79.4% year-over-year, from $297.87M to $61.38M.
What is the long-term trend for BioMarin Pharmaceuticals's pre-tax income?
Over 3 years (2021 to 2025), BioMarin Pharmaceuticals's pre-tax income has grown at a 89.1% compound annual growth rate (CAGR), from -$75.35M to $509.63M.
What does pre-tax income mean?
Total income from all sources — operating income plus non-operating items like interest income, investment gains, and other income — before the provision for income taxes.

Ask your AI about BioMarin Pharmaceuticals's pre-tax income.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude